H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Rockwell Medical (RMTI) to $7 from $9 and keeps a Buy rating on the shares post the Q3 report. The company’s largest customer made a special premium products order, but expects future volumes to decline due to supplier diversification, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMTI: